EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Viracta Therapeutics's enterprise value is $16.56 Mil.
Viracta Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-43.83 Mil. Therefore, Viracta Therapeutics's EV-to-EBITDA for today is -0.38.
The historical rank and industry rank for Viracta Therapeutics's EV-to-EBITDA or its related term are showing as below:
VIRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -929 Med: 0 Max: 13262.81
Current: -0.38
During the past 4 years, the highest EV-to-EBITDA of Viracta Therapeutics was 13262.81. The lowest was -929.00. And the median was 0.00.
VIRX's EV-to-EBITDA is ranked worse than 100% of 459
companies
in the Biotechnology industry
Industry Median: 10.28
vs VIRX: -0.38
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Viracta Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Viracta Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viracta Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Viracta Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viracta Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viracta Therapeutics's EV-to-EBITDA falls into.
Viracta Therapeutics's current Enterprise Value is $16.56 Mil.
Viracta Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Viracta Therapeutics's PE Ratio for today is calculated as:
Viracta Therapeutics's share price for today is $0.81.
Viracta Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Viracta Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Viracta Therapeutics (Viracta Therapeutics) Business Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIRX has been successfully added to your 